These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 23996149)

  • 1. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
    Castellucci LA; Cameron C; Le Gal G; Rodger MA; Coyle D; Wells PS; Clifford T; Gandara E; Wells G; Carrier M
    BMJ; 2013 Aug; 347():f5133. PubMed ID: 23996149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
    Gómez-Outes A; Terleira-Fernández AI; Suárez-Gea ML; Vargas-Castrillón E
    BMJ; 2012 Jun; 344():e3675. PubMed ID: 22700784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term benefits of preventing venous thromboembolic events.
    Cohen AT
    Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
    van der Hulle T; Kooiman J; den Exter PL; Dekkers OM; Klok FA; Huisman MV
    J Thromb Haemost; 2014; 12(3):320-8. PubMed ID: 24330006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
    Cohen A; Drost P; Marchant N; Mitchell S; Orme M; Rublee D; Simon TA; Sutton A
    Clin Appl Thromb Hemost; 2012 Nov; 18(6):611-27. PubMed ID: 22387582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
    Amin A; Jing Y; Trocio J; Lin J; Lingohr-Smith M; Graham J
    J Med Econ; 2014 Nov; 17(11):763-70. PubMed ID: 25078794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
    Spanos K; Giannoukas AD
    Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353. PubMed ID: 25556084
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353-4. PubMed ID: 25556083
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons.
    Hurst KV; Lee R; Milosevic I; Handa A
    Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):126-7. PubMed ID: 25933476
    [No Abstract]   [Full Text] [Related]  

  • 20. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
    Loke YK; Kwok CS
    J Clin Pharm Ther; 2011 Feb; 36(1):111-24. PubMed ID: 21198726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.